Blog Archieven - Page 14 of 25

Pharmacovigilance in the MENA Region

by Anna Kamocsai | May 26, 2022 | Pharmacovigilance

This blog focuses on pharmacovigilance (PV) in the MENA Region; the Middle East and North Africa. We do this by comparing the MENA region and Europe and inter-country differences in the MENA region. Local legislation and requirements will be discussed, such as...

Selecting a Pharmacovigilance Drug Safety Database

by Anna Kamocsai | Apr 7, 2022 | Pharmacovigilance

Selecting a Pharmacovigilance Drug Safety Database The WHO defines pharmacovigilance (PV) as the science and activities related to detecting, assessing, understanding, and preventing adverse effects of a medicinal product or any other possible drug-related problems. A...

How does the Russian invasion impact the pharmaceutical industry?

by Anna Kamocsai | Mar 10, 2022 | Clinical Research, Pharmacovigilance, Regulatory Affairs

Like the rest of the world, the pharmaceutical and biotech industries are beginning to worry about their ability to continue operations. And, with good reason. Russia’s invasion of Ukraine affects millions of people, not just in this Eastern European nation but...

How To Manage An Early Phase Oncology Study: Project Manager Insights

by Anna Kamocsai | Feb 23, 2022 | Clinical Research

Clinical development of oncology drugs has one of the lowest success rates of the development of Investigational New Drugs (INDs) for all disease categories, with less than 7% of phase I-tested oncology drugs achieving market approval. Moreover, the clinical...

How To Improve Patient Recruitment In Early Phase Oncology Trials

by Anna Kamocsai | Feb 9, 2022 | Clinical Research

The difficulties of recruiting in clinical trials, and particularly cancer patients in their early stages, can significantly obstruct the development of innovative treatments. There is an undeniable increase in demand for Early Phase Clinical studies in patients to...

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Pharmacovigilance in the MENA Region

Selecting a Pharmacovigilance Drug Safety Database

How does the Russian invasion impact the pharmaceutical industry?

How To Manage An Early Phase Oncology Study: Project Manager Insights

How To Improve Patient Recruitment In Early Phase Oncology Trials

Services

Contact

About Biomapas

Big Enough To Cover All Your Needs.
Small Enough To Care.

Clinical Research

Pharmacovigilance

Regulatory Affairs

Medical Information

Quality Assurance

Pharmacovigilance in the MENA Region

Selecting a Pharmacovigilance Drug Safety Database

How does the Russian invasion impact the pharmaceutical industry?

How To Manage An Early Phase Oncology Study: Project Manager Insights

How To Improve Patient Recruitment In Early Phase Oncology Trials

Big Enough To Cover All Your Needs.Small Enough To Care.

Clinical Research

Pharmacovigilance

Regulatory Affairs

Medical Information

Quality Assurance

We value your privacy.

Big Enough To Cover All Your Needs.
Small Enough To Care.